http://rdf.ncbi.nlm.nih.gov/pubchem/patent/PL-173963-B1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_07b71571160c289fbf5fc680dfea513f |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-275 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C255-54 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C255-57 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C255-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D271-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D257-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D285-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-41 |
| filingDate | 1993-03-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c285f6d0160975a4402c25a15cc4b313 |
| publicationDate | 1998-05-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | PL-173963-B1 |
| titleOfInvention | Pharmaceutical composition |
| abstract | A pharmaceutical composition containing the active ingredient and a pharmaceutically acceptable excipient, characterized in that the active ingredient is a compound of formula (I) in which: more than one halogen atom; r is 1 to 6, and when R6 in R1 is C3-6cycloalkyl then r can also be 0; R4 and R5 are independently selected from hydrogen or C1-2alkyl; R6 is hydrogen, methyl, C3-6 cycloalkyl optionally substituted with 1-3 m and methyl or one ethyl; X is YR2; Y is O; X2 is O; X3 is hydrogen; X4 is wherein the dashed line in formula (a) represents a single or double bond; X5 is H, OR8; R2 is independently selected from the group consisting of -CH3 and -CH2CH3, which groups are optionally substituted with one or more halogen atoms; R3 is CN; Z is C (O) OR1 4, C (Y ') NR10R14, C (SCH3) 3, 5-tetrazolyl, 3-or 5-oxadiazolyl [1,2,4], 2-oxadiazolyl [1,3,4] , 2-thiadiazolyl [1,3,4]; Y 'is O; R7 is C1-6alkyl optionally substituted with one or more C1-2alkyl groups optionally substituted with -C (O) OR8, -OR8; R8 is independently selected from hydrogen and R9; R9 is C1-4 alkyl optionally substituted with one to three fluoro atoms; R10 is OR8 or R11; R 11 is hydrogen or a C 1-4 alkyl group optionally substituted with one to three flucru atoms; R14 is hydrogen or R7; or a pharmaceutically acceptable salt thereof. E N 173963 B 1 GB |
| priorityDate | 1993-03-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 426.